Current development of podophyllotoxins.
The unique biological properties and therapeutic efficacy of the podophyllotoxin derivatives, Vumon (VM26, teniposide) and Vepesid (VP16-213, etoposide), are stimulating the interest of both laboratory and clinical researchers. Investigations on new pharmaceutical formulations, pharmacokinetics and metabolism are providing more appropriate information in drug administration; experimental chemotherapy indicates that, among others, cytosine arabinoside and cisplatin are highly synergistic with podophyllotoxins; single agent and combination treatment clinical trials are defining the respective role of Vumon and Vepesid in cancer chemotherapy.
D002626:Chemistry, Pharmaceutical; D004339:Drug Compounding; D004355:Drug Stability; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000378:metabolism / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D013713:Teniposide / Q000378:metabolism* / Q000494:pharmacology*
D005047:Etoposide; D013713:Teniposide; D011034:Podophyllotoxin